Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Jefferies
Tweet
Share
E-mail
Get Alerts AMPH Hot Sheet
Price: $21.43 -1.43%
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 19
Rating Summary:
2 Buy, 8 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 19
Join SI Premium – FREE
Jefferies lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $20.00 (from $21.00) while maintaining a Buy rating. 1Q EPS of $0.09 was ahead of consensus estimates on lower spending.
Management reported that the FDA recently completed pre-approval inspections for 5 of the 6 ANDA’s on file and noted that 4 ANDAs have 2017 GDUFA dates while one product is a pre-GDUFA ANDA.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS
- Giant Biogene Holding Co (2367:HK) PT Raised to HK$46 at Macquarie
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & Co, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
